BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 33140310)

  • 21. RNA binding protein RBM14 promotes radio-resistance in glioblastoma by regulating DNA repair and cell differentiation.
    Yuan M; Eberhart CG; Kai M
    Oncotarget; 2014 May; 5(9):2820-6. PubMed ID: 24811242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A curcumin derivative hydrazinobenzoylcurcumin suppresses stem-like features of glioblastoma cells by targeting Ca
    Shin HJ; Lee S; Jung HJ
    J Cell Biochem; 2019 Apr; 120(4):6741-6752. PubMed ID: 30390339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
    William D; Walther M; Schneider B; Linnebacher M; Classen CF
    PLoS One; 2018; 13(1):e0191511. PubMed ID: 29352318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of reactive oxygen species.
    Gersey ZC; Rodriguez GA; Barbarite E; Sanchez A; Walters WM; Ohaeto KC; Komotar RJ; Graham RM
    BMC Cancer; 2017 Feb; 17(1):99. PubMed ID: 28160777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.
    Kim JS; Shin DH; Kim JS
    J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
    Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
    Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic targeting of malignant glioma.
    Alexandru-Abrams D; Jadus MR; Hsu FP; Stathopoulos A; Bota DA
    Anticancer Agents Med Chem; 2014; 14(8):1075-84. PubMed ID: 25175690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HMGB1-Induced p62 Overexpression Promotes Snail-Mediated Epithelial-Mesenchymal Transition in Glioblastoma Cells via the Degradation of GSK-3β.
    Li H; Li J; Zhang G; Da Q; Chen L; Yu S; Zhou Q; Weng Z; Xin Z; Shi L; Ma L; Huang A; Qi S; Lu Y
    Theranostics; 2019; 9(7):1909-1922. PubMed ID: 31037147
    [No Abstract]   [Full Text] [Related]  

  • 29. Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway.
    Nakano I; Joshi K; Visnyei K; Hu B; Watanabe M; Lam D; Wexler E; Saigusa K; Nakamura Y; Laks DR; Mischel PS; Viapiano M; Kornblum HI
    Neuro Oncol; 2011 Jun; 13(6):622-34. PubMed ID: 21558073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
    Reddy RG; Bhat UA; Chakravarty S; Kumar A
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):165-179. PubMed ID: 32638092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
    Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
    Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting cancer stem cells for treatment of glioblastoma multiforme.
    Cho DY; Lin SZ; Yang WK; Lee HC; Hsu DM; Lin HL; Chen CC; Liu CL; Lee WY; Ho LH
    Cell Transplant; 2013; 22(4):731-9. PubMed ID: 23594862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma.
    Shevchenko V; Arnotskaya N; Korneyko M; Zaytsev S; Khotimchenko Y; Sharma H; Bryukhovetskiy I
    Oncol Rep; 2019 May; 41(5):3080-3088. PubMed ID: 30864699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma.
    Miyashita K; Kawakami K; Nakada M; Mai W; Shakoori A; Fujisawa H; Hayashi Y; Hamada J; Minamoto T
    Clin Cancer Res; 2009 Feb; 15(3):887-97. PubMed ID: 19188159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycogen synthase kinase-3 inhibition in glioblastoma multiforme cells induces apoptosis, cell cycle arrest and changing biomolecular structure.
    Acikgoz E; Güler G; Camlar M; Oktem G; Aktug H
    Spectrochim Acta A Mol Biomol Spectrosc; 2019 Feb; 209():150-164. PubMed ID: 30388586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
    Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
    J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
    Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A
    Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glioblastoma cancer stem cell biology: Potential theranostic targets.
    Sharifzad F; Ghavami S; Verdi J; Mardpour S; Mollapour Sisakht M; Azizi Z; Taghikhani A; Łos MJ; Fakharian E; Ebrahimi M; Hamidieh AA
    Drug Resist Updat; 2019 Jan; 42():35-45. PubMed ID: 30877905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.